## 

## 

|||||Page|
|---|---|---|---|---|
|Trustees and Officers|.|||2-3|
|Chairman's<br>Statement||||4-5|
|Trustees' Report||||6-9|
|Statement ofTrustees'|responsibilities||||
|Report ofthe Independent||Auditor||10-11|
|Grants awarded||||12|
|Statement ofFinancial|Activities||. ....|13|
|Balance sheet||||14|
|Cash Flow Statement|.|||15|
|Notes to the Financial|Statements|||16-21|





## 

## 

|Terry Madden|Chairman|||
|---|---|---|---|
|Roger Allsopp||||
|Tony Cottam||||
|Professor Jonathan Cole||||
|Professor Max Crispin||||
|Professor Diana Eccles|Dean ofthe Faculty ofMedicine,|University|of Southampton.|
|Stella Gardener|Retired 23.04.21|||
|Professor SirCharles George||||
|Luke March|Appointed 23.04.21|||
|Nick Page||||
|Angela Suggate FCCA||||
|Michael Wilkins||||



## 

|Independent|Auditors|Sheen Stickland|
|---|---|---|
|||Chartered<br>Accountants|
|||Statutory Auditors|
|||7East Pallant|
|||Chiche ster|
|||West Sussex|
|||PO191TR|
|Honorary|Solicitors|Womble Bond Dickinson (UK) LLP|
|||Oceana House|
|||Commercial Road|
|||Southampton|
|||SO151GA|





## 

|Faculty of|Medicine, University|ofSouthampton.|
|---|---|---|
|Faculty of|Medidne,<br>University|ofSouthampton|
|Faculty of|Medicine, University|ofSouthampton|
|Faculty of|Environmental<br>and Life Sciences||
|University|ofSouthampton||
|Faculty of|Environmental<br>and Life Sciences||
|University|ofSouthampton||
|Faculty of|Physical Sciences and Engineering||
|University|ofSouthampton||
|Faculty of|Medicine, University|ofSouthampton|
|Faculty of|Physical Sciences and Engineering,||
|University|ofSouthampton||
|Faculty of|Medicine, University|ofSouthampton|
|Faculty of|Medicine, University|ofSouthampton|
|Faculty of|Medicine, University|ofSouthampton|
|Faculty of|Environmental<br>and Life Sciences,||
|University|ofSouthampton||
|Faculty of|Environmental<br>and Life Sciences,||
|University|ofSouthampton||



## 



## 







## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 



## 

||||||||||Total|
|---|---|---|---|---|---|---|---|---|---|
||||||||||value|
||||||||||R|
|AB01|DrZoe Walters||||||||49,986|
||Faculty ofMedicine|||||||||
||PhD Studensthipjointly<br>funded with Rosetrees|||Trust||||||
||Student-Jack<br>Hamngton|||||||||
||Investigating<br>the therapeutic||efficacy ofEZH2inhibitors|||forthe treatment of||||
||diseases<br>with pathogenic|histone modifying<br>enzyme mutations.||||||||
|AB02|3"Year Medical Student Project Presentation|||Grants|||||1,000|
|AB03|Dr Franklin de Nobrega||||||||20,000|
||Faculty ofthe Environment||and Life Sciences|||||||
||Vsing phages togive new life tooldantibiotics|||against superbugs||||||
|AB04|Dr Adnan<br>Khan||||||||19,933|
||Faculty ofMedicine|||||||||
||A clinical study evaluatihg|biomarkers<br>ofimmunosenescencein||||||the||
||progression ofAge Related||Macular DegeneratIon||(The Immuno|||AMO Study)||
|AB05|Dr Nicole Prior||||||||20,000|
||Faculty ofthe Environment||and Life Sciences|||||||
||Chemically defined biomimetic hydrogels<br>tosupport <br>pancreas organoids forthe development ofclinical||||human<br> therapies||ilver|and||
||Annual<br>Total 2021||||||||110,919|
||Annual<br>Tota/2020||||||||91,22B|





## 

|Balance Sheet asat 31|December 2021||||
|---|---|---|---|---|
|||Note|2021|2020|
|Fixed Assets|||||
|Tangible Assets||10|||
|Inmstments||11|1,339,252|868,776|
||||1,339,252|868,776|
|Current Assets|||||
|lffMstmen'ts||12|31,503|32,624|
|Debtors||13|50,512|50,604|
|Cash at bank and in hand|||670,924|129,175|
||||752,939|212,403|
|Current Uabilities|||||
|Amounts<br>falling due within|one year|14|(256,993)|(394,771)|
|Net Current Assets I(Liabilities)|||495,946|(182,368)|
|Total Assets less Cunsnt Uabilities|||1,835,198|686,408|
|Liabilities|||||
|Amounts<br>falling due after|more than one year|15|(171,019)|(146,715)|
|||16|1,664,179|539,693|
|Funds|||||
|Unrestricted|General|18|541,698|477,295|
|Restricted||17|1,122,481|62,398|
|Total Funds|||1,664,179|539,693|





|Statement ofFinancial|Acdvities|Acdvities|||||||
|---|---|---|---|---|---|---|---|---|
|Forthe Year Ended 31stDecember 2021|||||||||
|||||Note|Unrestricted|Restricted|Total|Total|
||||||Funds|Funds|2021|2020|
||||||E|E|E|E|
|Income and endowments||from|||||||
|Donations||||2a|9,035|10,000|19,035|42,319|
|Legacies||||2b|16,366|1,050,000|1,066,366|151,000|
|Other trading<br>actlNties||||||2,641|2,641|3,560|
|Investment<br>income|||||50,903||50,903|45,979|
|Total|||||76,304|1,062,641|1,138,945|242,858|
|Expenditure<br>on|||||||||
|Raising Funds||||4|15,302|-|15,302|17,114|
|Charitable<br>actiuties||||5,6|120,953|(2,442)|116,511|94,286|
|Total|||||136,255|(2,442)|133,813|111,400|
|Other recognised<br>gains/(losses)|||||||||
|Gains/(losses)<br>on irnestment||assets|||119,354||119,354|(193,733)|
|Net income/(expenditure)|||||59,403|1,065,083|1,124,486|(62,275)|
|Transfers<br>between funds||||17|5,000|(5,000)|||
|Net movement<br>in funds|||||64,403|1,060,083|1,124,486|(62,2?5)|
|Reconciliation cftunds|||||||||
|Balances brought<br>Onward|at|1"January|2021||477,295|62,398|539,693|601,968|
|Balances carried Ibrward|at|31"December 2021|||541,698|1,122,481|1,664,179|539,693|





## 

|Cash Flow Statement|||||||||
|---|---|---|---|---|---|---|---|---|
|||||||2021||2020|
|Cash f'rom Operating<br>Aclvities||Note 1||||840,846||(20,135)|
|Cash low from Investing|||||||||
|Purchase ofFixed Asset Investments|||||(500,000)||||
|Sale ofFixed Asset Inv|stments||||150,000||50,000||
|Sale ofCunent Asset Investments|||||||17,500||
|Distributions<br>Receimd|||||50,903||45,979||
|||||||(299,097)||113,479|
|Change<br>in cash and cash|equivalents||in the||period|541,749||93,344|
|Cash and cash equivalents|at 1stJanuary|||2021||129,175||35,831|
|Cash and cash eqnivalenm|at 31st|Oecemher|||2821|670,924||129,175|



## 

|Cash from operating<br>Ac|tivities||||
|---|---|---|---|---|
|Net income/(expenditure)|for reporting|period per SOFA|1,124,486|(62,275)|
|Adjustments<br>Ibr:|||||
|Distributions<br>received|||(50,903)|(45,979)|
|Decrease in Debtors|||92|8,132|
|Increase<br>/ (Decrease)|in Creditors||1,482|(19,005)|
|(Decrease) in Grants|payable||(114,957)|(94,741)|
|(Gain)/Loss<br>on investments|||(119,354)|193,733|
||||840,846|(20,135)|





## 

## 



## 

|2a. Donations|2021|2020|
|---|---|---|
|Trusts and foundations|12,000|30,950|
|Individuals|6,366|6,313|
|Gift aid|647|21|
|Corporate|22|35|
|Other||5,000|
||19,035|42,319|
|2b. Legacies|||
|Legacies|1,066,366|151,000|



## 

|||2021|2020|
|---|---|---|---|
|Income from UK quoted in~tments||50,903|45,979|
|||50,903|45,979|
|4.|Raising Funds|||



|||Unrestricted|Restricted|2021|2020|
|---|---|---|---|---|---|
|Eat Costs|||||1,750|
|Brochures|and Leallets|3,126||3,126|2,990|
|Admrtising||260||260|690|
|Support Costs||11,916||11,916|11,684|
|||15,302||15,302|17,114|



## 

|Grant|||
|---|---|---|
|Funding of|Support||
|Activities|Costs|Total|
||E||
|96,929|21,583|118,511|
|96,929|21,583|118,511|





## 

## 

|6.<br>Allocatio|n ofSupport Costa||||
|---|---|---|---|---|
|||Raising|Charitable|Total|
|||Funda|Activities||
|||K||E|
|Oflice Costs||1,421|1,528|2,949|
|Professional|Fees|10,495|16,154|26,649|
|Audit Fees|||3,900|3,900|
|||11,918|21,582|33,498|



## 

## 

## 

## 

|9. Auditors and In|dependent|Examiners remunera6on|||
|---|---|---|---|---|
||||2021||
||||K||
|Auditors/independent|Examiners|Senices|3,900|2,400|
||||3.900|2.400|





## 

## 

|10. Tangible|Fixed|Assets|||||
|---|---|---|---|---|---|---|
||||||Fixtures, Fittings||
||||||and|Equipment|
|||||||F.|
|Cost at 1» January||2021||||190|
|Additions|||||||
|Disposals|||||||
|Cost at 31~ December 2021||||||190|
|Accumulated|depreciation||at 1" January|2021||190|
|Charge ibr year|||||||
|Disposals|||||||
|Accumulated|depreciation||at 31" December 2021|||190|
|Net BookValue|||||||
|31" December|2021||||||
|31" December|2020||||||
|11.Investments<br>atmarket value: fixed assets|||||||
|Equities - UK|||||||
|Market Value|at 1st|January|2021|||868,776|
|Additions||||||500,000|
|Disposals||||||(131,939)|
|Unrealised<br>Gain Ibr the year||||||102,415|
|Market value|at 31stDecember 2021|||||1,339,252|



|Go~ant|Stocks|||
|---|---|---|---|
|Market Value at 1stJanuary||2021|32,624|
|Additions||||
|Disposals||||
|Unrealised|Loss for the year||(1,121)|
|Market value at 31stDecember 2021|||31,503|





## 

## 

|13. Debtors||||
|---|---|---|---|
|||2021|2020|
|||E||
|Other debtors||50,095|50,187|
|Prepayments||417|417|
|||50,512|50,604|
|14Creditors: amounts|falling due within one year|||
|||2021|2020|
|Grants payable||248,976|388,236|
|Accruals||8,017|6,535|
|||256,993|394,771|



## 

|15.Cr|editors: amounts<br>falling due afiar|more than one year||
|---|---|---|---|
|||2021|2020|
|Grants|payable|171,019|146,715|
|||171,019|146,715|



## 

||||||Unrestricted|Restricted|Total|
|---|---|---|---|---|---|---|---|
||||||Funds|Funds|Funds|
||||||||R|
|Fixed|Assets||||848,632|490,620|1,339,252|
|Current||Assets|||82,015|670,924|752,939|
|Current||Liabilities|||(244,493)|(12,500)|(256,993)|
|Amounts||falling|due|alter more||||
|than|1 year||||(144,457)|(26,562)|(171,019)|
|Total|Net Assets||||536,697|1 127462|1,664,179|





|17. Restricted|17. Restricted|Funds||||||
|---|---|---|---|---|---|---|---|
|||||||2021|2020|
|||||||K|f|
|Opening|balance at||1» January||2021|62,398|95,539|
|Net moment||in restricted||funds||1,065,083|(33,141)|
|Transfer|to unrestricted||general<br>funds|||(5,000)||
|Balance|at 31|December||2021||1,122,481|62,398|



|specIc purpose<br>by the Trustees|at a future date.|||||
|---|---|---|---|---|---|
||Opening|Incoming|Resources|Transfers|Closing|
||balance|Resources|Expended|between|balance at|
||at 1st|||funds|3162|
||January||||December|
||2021||||2021|
|Allergies|9,506||||9,506|
|Brain Injury|9,089||||9,089|
|Cancer|17,477|1,062,641|||1,080,118|
|Cancer [Cenical]|||2,442||2,442|
|Diabetes|135||||135|
|Meningitis|7,247||||7,247|
|Staa Mills lund|11,882||||11,882|
|States ofGuernsey|5,000|||(5,000)||
|Other disease specilic funds<br>Tolal|2,062<br>62,388|1,062,641|2,442|~5,000)|2,062<br>1,122,481|



## 

||||||2021|2020|
|---|---|---|---|---|---|---|
||||||f|K|
|Opening|balance at 1||January|2021|477,295|506,429|
|Net moment||in Free t0nds|||59,403|(29,134)|
|Transfsr|from|Restricted|Funds||5,000||
|Balance|at 31"December 2021||||541,698|4?7,295|



##